title: Use of subcutaneous enoxaparin compared to intravenous heparin and oral phenprocoumon in the setting of cardioversion--the ACE study (Anticoagulation in Cardioversion using Enoxaparin).
abstract: The mode and duration of anticoagulation in the setting of cardioversion of atrial fibrillation-either with or without guidance by transesophageal echocardiography (TEE)-is still an unresolved issue. Oral anticoagulation with warfarin or phenprocoumon is frequently used but may be associated with an increased risk of bleeding complications or, conversely, episodes of undercoagulation. Moreover, it takes several days to reach full anticoagulation with oral compounds. This phase may be covered with intravenous heparin but this requires prolonged hospitalization. Low-molecular weight heparin is an attractive alternative as it not only provides a safe and predictable level of anticoagulation with few side effects but can also be administered safely on an outpatient basis. In addition, anticoagulation monitoring is usually unnecessary. The ACE study (Anticoagulation in Cardioversion using Enoxaparin) compared the safety and efficacy of subcutaneous enoxaparin with intravenous heparin/oral phenprocoumon before and after cardioversion (stratified to TEE guidance or no TEE guidance). This article summarizes the study rationale and design. The results will be published shortly.
authors.affiliation: Rheinisch-Westfälische Technische Hochschule Aachen. cstellbrink@ukaachen.de
authors.forename: Christoph
authors.initials: C
authors.lastname: Stellbrink
authors.forename: Uwe
authors.initials: U
authors.lastname: Nixdorff
authors.forename: Thomas
authors.initials: T
authors.lastname: Hofmann
authors.forename: Walter
authors.initials: W
authors.lastname: Lehmacher
authors.forename: Werner Günther
authors.initials: WG
authors.lastname: Daniel
authors.forename: Peter
authors.initials: P
authors.lastname: Hanrath
authors.forename: Christoph
authors.initials: C
authors.lastname: Geller
authors.forename: Andreas
authors.initials: A
authors.lastname: Mügge
authors.forename: Walter
authors.initials: W
authors.lastname: Sehnert
authors.forename: Caroline
authors.initials: C
authors.lastname: Schmidt-Lucke
authors.forename: Jan-André
authors.initials: JA
authors.lastname: Schmidt-Lucke
mesh_terms: D000284:Administration, Oral; D017548:Echocardiography, Transesophageal; D004554:Electric Countershock; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D015337:Multicenter Studies as Topic; D010644:Phenprocoumon / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013923:Thromboembolism / Q000517:prevention & control*
chemical_list: D017984:Enoxaparin; D006493:Heparin; D010644:Phenprocoumon